Koron Pharmaceuticals: The follow-up project pipeline mainly focuses on the two core treatment areas of CNS and endocrinology.

On April 3, Colen Pharmaceuticals stated during an institutional research that their first class-1 innovative drug developed by Colen Drug Research Institute is a new drug in the field of anesthesia, which has already been approved for clinical trials and is currently in the clinical trial phase. In their current pipeline, projects in the PCC stage mainly focus on the CNS field and anti-fungal infection direction, with progress in anti-fungal drugs, which have entered the PCC stage. Projects for schizophrenia and depression have also passed screening. The company's future pipeline will mainly focus on the two core treatment areas of CNS and endocrinology.